Consolidated Balance Sheets Arcadia Biosciences, Inc. experienced a decrease in total assets and stockholders' equity by June 30, 2025, primarily due to reduced cash and noncurrent notes Key Balance Sheet Figures (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change | % Change | | :-------------------------------- | :------------ | :---------------- | :----- | :------- | | Total Assets | $7,788 | $13,517 | $(5,729) | -42.38% | | Current Assets | $7,579 | $9,242 | $(1,663) | -18.00% | | Cash and cash equivalents | $1,376 | $4,242 | $(2,866) | -67.56% | | Short-term investments | $3,067 | — | $3,067 | N/A | | Note receivable — noncurrent, net | — | $3,966 | $(3,966) | -100.00% | | Total Liabilities | $3,255 | $7,294 | $(4,039) | -55.37% | | Common stock warrant and option liabilities | $1,416 | $2,731 | $(1,315) | -48.15% | | Total Stockholders' Equity | $4,533 | $6,223 | $(1,690) | -27.16% | | Accumulated deficit | $(280,737) | $(278,878) | $(1,859) | 0.67% | - The company's cash and cash equivalents significantly decreased by 67.56% from $4,242 thousand at December 31, 2024, to $1,376 thousand at June 30, 20252 - A new line item, Short-term investments, appeared with $3,067 thousand as of June 30, 2025, which was not present at December 31, 20242 - The noncurrent note receivable, net of allowance for credit losses, was fully eliminated by June 30, 2025, from $3,966 thousand at December 31, 20242 Consolidated Statements of Operations and Comprehensive Income (Loss) Arcadia Biosciences, Inc. reported a net loss for Q2 and H1 2025, primarily due to a significant credit loss and reduced gain on asset sales Key Operating Results (in thousands, except per share data): 3 Months Ended June 30, 2025 | Metric | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | Change | % Change | | :------------------------------------------ | :--------------------------- | :--------------------------- | :----- | :------- | | Product Revenues | $1,455 | $1,306 | $149 | 11.41% | | Total Revenues | $1,455 | $1,306 | $149 | 11.41% | | Cost of Revenues | $824 | $633 | $191 | 30.17% | | Gain on sale of intangible assets | — | $(4,000) | $4,000 | -100.00% | | Change in fair value of contingent consideration | $(1,000) | — | $(1,000) | N/A | | Selling, general and administrative | $2,123 | $2,683 | $(560) | -20.87% | | (Loss) income from operations | $(501) | $1,980 | $(2,481) | -125.30% | | Credit loss | $(4,489) | — | $(4,489) | N/A | | Net (loss) income from continuing operations | $(4,458) | $1,850 | $(6,308) | -341.00% | | Net (loss) income attributable to common stockholders | $(4,458) | $1,061 | $(5,519) | -519.98% | | Basic and diluted EPS from continuing operations | $(3.26) | $1.36 | $(4.62) | -339.71% | Key Operating Results (in thousands, except per share data): 6 Months Ended June 30, 2025 | Metric | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change | % Change | | :------------------------------------------ | :--------------------------- | :--------------------------- | :----- | :------- | | Product Revenues | $2,655 | $2,293 | $362 | 15.79% | | Total Revenues | $2,655 | $2,293 | $362 | 15.79% | | Cost of Revenues | $1,506 | $1,104 | $402 | 36.41% | | Gain on sale of intangible assets | $(750) | $(4,000) | $3,250 | -81.25% | | Change in fair value of contingent consideration | $(2,000) | — | $(2,000) | N/A | | Selling, general and administrative | $3,861 | $4,745 | $(884) | -18.63% | | (Loss) income from operations | $29 | $392 | $(363) | -92.60% | | Credit loss | $(4,489) | — | $(4,489) | N/A | | Net (loss) income from continuing operations | $(1,859) | $903 | $(2,762) | -305.87% | | Net (loss) income attributable to common stockholders | $(1,859) | $(1,362) | $(497) | 36.49% | | Basic and diluted EPS from continuing operations | $(1.36) | $0.66 | $(2.02) | -306.06% | - A significant credit loss of $4,489 thousand was recognized in both the three and six months ended June 30, 2025, which was not present in the prior year periods, contributing heavily to the net loss4 - The gain on sale of intangible assets decreased substantially from $(4,000) thousand in Q2 2024 to zero in Q2 2025, and from $(4,000) thousand to $(750) thousand for the six-month period, indicating fewer large asset sales4 - Selling, general and administrative expenses decreased by 20.87% for the three-month period and 18.63% for the six-month period, indicating cost control efforts4 Consolidated Statements of Cash Flows Arcadia Biosciences, Inc. experienced a net decrease in cash for H1 2025, driven by operating activities and reduced investing proceeds Key Cash Flow Figures (in thousands) | Metric | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | Change | % Change | | :------------------------------------------ | :--------------------------- | :--------------------------- | :----- | :------- | | Net cash used in operating activities | $(3,621) | $(5,666) | $2,045 | -36.09% | | Net cash provided by investing activities | $750 | $4,647 | $(3,897) | -83.87% | | Net cash provided by financing activities | $5 | $5 | $0 | 0.00% | | Net decrease in cash and cash equivalents | $(2,866) | $(1,014) | $(1,852) | 182.64% | | Cash and cash equivalents — end of period | $1,376 | $5,504 | $(4,128) | -75.00% | - Net cash used in operating activities decreased by 36.09% to $(3,621) thousand for the six months ended June 30, 2025, compared to $(5,666) thousand in the prior year, despite a higher net loss6 - Investing activities provided significantly less cash, dropping by 83.87% from $4,647 thousand in 2024 to $750 thousand in 2025, mainly due to lower proceeds from the sale of intangible assets and investments6 - Noncash investing activities included the receipt of Above Food Ingredients, Inc. common stock with a fair value of $3,067 thousand in 20256
Arcadia Biosciences(RKDA) - 2025 Q2 - Quarterly Results